⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Ethypharm and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Ethypharm
↗Saint-Cloud, France
Ethypharm is a mid-sized international specialty pharmaceutical company with strong European roots. The company focuses on developing, manufacturing, and marketing essential medicines, with a primary emphasis on the Central Nervous System (CNS)—specifically severe pain management and addiction—and hospital injectables.
Ethypharm manages the entire pharmaceutical value chain, from R&D to commercialization, and operates as a CDMO (Contract Development and Manufacturing Organization) for third parties. It maintains a significant manufacturing footprint in Europe and China, serving global markets through direct operations and strategic partnerships.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$400M-$500M
Founded:1977
Ownership:private
Status:operating
FUNDING
Stage:Private Equity-Backed
Total Raised:$1.6B
Investors:PAI Partners
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, Injectables
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Medochemie (Licensing for Nefopam), Dr. Reddy's (Licensing for Celecoxib formulation)
COMPETITION
Position:Niche Player
Competitors:BDSI, Flexion Therapeutics, Zogenix
LEADERSHIP
Key Executives:
Bertrand Deluard - CEO
LINKS
Website:ethypharm.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Ethypharm. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.